Literature DB >> 963178

On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial.

L S Freedman, S J White.   

Abstract

Mesh：

Year:  1976        PMID： 963178

Source DB:  PubMed          Journal:  Biometrics        ISSN： 0006-341X            Impact factor:   2.571


× No keyword cloud information.
  22 in total

1.  Microcomputer voice-response telephone entry for balanced clinical trial randomization.

Authors:  S Cheung; S M Entine; J H Klotz
Journal:  J Med Syst       Date:  1977       Impact factor: 4.460

2.  Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.

Authors:  Desmond Curran; Carmelo Pozzo; Jerzy Zaluski; Magdalena Dank; Carlo Barone; Vahur Valvere; Suayib Yalcin; Christian Peschel; Miklós Wenczl; Erdem Goker; Roland Bugat
Journal:  Qual Life Res       Date:  2009-07-01       Impact factor: 4.147

3.  Minimisation: the platinum standard for trials?. Randomisation doesn't guarantee similarity of groups; minimisation does.

Authors:  T Treasure; K D MacRae
Journal:  BMJ       Date:  1998-08-08

4.  Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.

Authors:  A Cometta; T Calandra; H Gaya; S H Zinner; R de Bock; A Del Favero; G Bucaneve; F Crokaert; W V Kern; J Klastersky; I Langenaeken; A Micozzi; A Padmos; M Paesmans; C Viscoli; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Authors:  Hervé Bonnefoi; Martine Piccart; Jan Bogaerts; Louis Mauriac; Pierre Fumoleau; Etienne Brain; Thierry Petit; Philippe Rouanet; Jacek Jassem; Emmanuel Blot; Khalil Zaman; Tanja Cufer; Alain Lortholary; Elisabet Lidbrink; Sylvie André; Saskia Litière; Lissandra Dal Lago; Véronique Becette; David A Cameron; Jonas Bergh; Richard Iggo
Journal:  Lancet Oncol       Date:  2011-05-11       Impact factor: 41.316

6.  Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.

Authors:  S Leyvraz; S Piperno-Neumann; S Suciu; J F Baurain; M Zdzienicki; A Testori; E Marshall; M Scheulen; T Jouary; S Negrier; J B Vermorken; E Kaempgen; X Durando; D Schadendorf; R Karra Gurunath; U Keilholz
Journal:  Ann Oncol       Date:  2014-02-07       Impact factor: 32.976

7.  PELICAN: A quality of life instrument for childhood asthma: study protocol of two randomized controlled trials in primary and specialized care in the Netherlands.

Authors:  Stephanie van Bragt; Lisette van den Bemt; Bart Thoonen; Chris van Weel; Peter Merkus; Tjard Schermer
Journal:  BMC Pediatr       Date:  2012-08-30       Impact factor: 2.125

Review 8.  Randomization in substance abuse clinical trials.

Authors:  Sarra L Hedden; Robert F Woolson; Robert J Malcolm
Journal:  Subst Abuse Treat Prev Policy       Date:  2006-02-06

9.  Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983.

Authors:  Ronald de Wit; Iwona Skoneczna; Gedske Daugaard; Maria De Santis; August Garin; Nina Aass; Alfred J Witjes; Peter Albers; Jeffery D White; José R Germa-Lluch; Sandrine Marreaud; Laurence Collette
Journal:  J Clin Oncol       Date:  2012-01-23       Impact factor: 44.544

10.  An investigation of minimisation criteria.

Authors:  Angie Wade; Huiqi Pan; Simon Eaton; Agostino Pierro; Evelyn Ong
Journal:  BMC Med Res Methodol       Date:  2006-03-15       Impact factor: 4.615
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.